Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 26c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.40), $0.26 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
• Credo Technology shares rise on analyst support and conference comments